Please login to the form below

Not currently logged in

Eisai and SFJ Pharma form partnership

Eisai has agreed a partnership with US-based SFJ Pharma in a bid to speed up development of its pipeline

Eisai has entered into a collaborative development agreement with SFJ Pharma, a wholly-owned subsidiary of SFJ Pharmaceuticals, in an effort to further accelerate the late-stage clinical development of its pipeline.

Eisai said the deal will effectively leverage internal resources, as well as build a new partnership scheme. Under the scheme, Eisai will accept funding from external parties to conduct phase III studies for promising new drug candidates in order to push forward with numerous development programmes simultaneously and as quickly as possible.

The Japanese pharmaceutical company has entered into a collaborative development agreement with SFJ to conduct phase III studies with E7080 (lenvatinib) in thyroid cancer. These late-stage studies will be conducted by Eisai and wholly funded by SFJ, with Eisai paying SFJ milestone payments if E7080 obtains regulatory approval. If the compound is approved, all commercial rights shall remain with Eisai.

Eisai has previously established a strategic collaboration with Quintiles, through which it has been advancing multiple candidate anticancer compounds for proof of concept studies.

7th September 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Beyond the event
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...